script.reportAU
Cardiovascular

Aliskiren

Brand: Rasilez®

PBAC's latest decision on Aliskiren: Not recommended (2010). Considered for For the treatment of hypertension.

PBAC outcome
Not recommended
2010
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2010
Submissions
1
2010 → 2010

Eligible population

patients treated for hypertension where an agent acting on the renin-angiotensin system (RAS) is considered to be clinically indicated by the prescriber

Therapy area
Cardiovascular
Evidence base
RCT
Key trials
Trial 2201, Trial 2309, Trial 2351, Trial 2203, Trial 2327, Trial 2331, Trial 2306, Trial 2307, Trial 2344, Trial 2316, C2201-AVOID, Ferdinand 2010, ASPIRE (2010)
Comparator
irbesartan (main); valsartan, ramipril, lisinopril (secondary); PBAC considered should include mix of all PBS-subsidised antihypertensive agents
Economic model
Cost-minimisation
ICER note
Cost minimisation analysis performed; no ICER calculated

Why PBAC said no

Reasons cited in the latest PSD: no reduction in cardiovascular mortality and morbidity demonstrated (unlike ACE inhibitors and AIIRAs), no additional indications (heart failure, post-MI, vascular disease, renal disease), no long-term safety data, uncertain clinical need, uncertain cost effectiveness
Open on full dashboard →